Morphosys, GeneFrontier Expand HuCAL Deal to Include Antibody Development

Jan 25, 2007

NEW YORK (GenomeWeb News) — Morphosys today said it has expanded a 2-year-old marketing agreement with GeneFrontier to include HuCAL-based research, and the sales of any resulting antibody products.

The original agreement, signed in 2004, gave Tokyo-based GeneFrontier rights to market the Human Combinatorial Antibody Library technology in Japan for research and therapeutic applications.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Cloud Ready

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

The Science and Policy Connection

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

The New Yeast

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

This Week in Cell

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.

Main menu